Are Peptides Legal? Prescription Peptides vs Research Chemicals in the U.S.

Are peptides legal in the United States?

Yes, with conditions. A peptide is legal to use when it is an FDA-approved drug prescribed by a licensed clinician, or when a state-licensed pharmacy compounds it under section 503A using an ingredient FDA permits. Peptides sold as “research chemicals” or “not for human consumption” fall outside both lanes, and FDA treats them as unapproved drugs marketed for human use.

Educational information, not legal or medical advice. Current as of September 2026.

What “legal” means for a peptide: two lawful lanes and a grey zone

U.S. law regulates drugs, not “peptides,” and asks one practical question: is this an approved drug, or is it compounded lawfully for a specific patient?

• Lane 1, FDA-approved peptide drugs. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and bremelanotide (Vyleesi, approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder) are legal on a prescription, dispensed by a licensed pharmacy. See our post on what PT-141 is.
• Lane 2, compounded prescription peptides. A state-licensed pharmacy or physician may compound for an individual patient under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA is blunt about what that does not mean: “Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.” Approved drugs are reviewed by FDA before marketing.
• The grey zone, “research use only” vials. A disclaimer is not a legal pathway: FDA treats these products as unapproved new drugs.

Prescription peptides: 503A versus 503B compounding

• Section 503A covers traditional compounding by a state-licensed pharmacy or physician. FDA’s summary is specific: drugs must be “compounded based on the receipt of valid patient-specific prescriptions.” That is the lane telehealth prescriptions use.
• Section 503B created a voluntary category, outsourcing facilities, under the Drug Quality and Security Act of 2013. They register with FDA, follow current good manufacturing practice, and may distribute with or without a patient-specific prescription.

For a 503A compounder, the active ingredient, the bulk drug substance, must itself be lawful. FDA gives three bases, and a substance needs only one: a USP or NF monograph, status as a component of an FDA-approved drug product where no monograph exists, or a place on FDA’s 503A bulks list at 21 CFR 216.23. Without one of those, no 503A pharmacy may lawfully compound with it.

A second limit applies to every ingredient, not only peptides: a 503A pharmacy may not regularly compound what is essentially a copy of a commercially available approved drug. FDA states the test: a product is essentially a copy if it “has the same active pharmaceutical ingredient(s) (API) as the commercially available drug product in the same, similar or an easily substitutable strength, and the commercially available drug product can be used by the same route of administration (regardless of how it is labeled) prescribed for the compounded drug product.” The exception is narrow, and applies “unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.” Both prongs matter: where an approved product matches on strength and route, a compounded version needs that documented, patient-specific reason; a different route is assessed separately.

Where GLP-1s fit now

FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025. Both are available again, so the essentially-a-copy restriction applies to GLP-1s. FDA has said separately that it does not intend to pursue a compounder over whether copying is happening “regularly or in inordinate amounts” when four or fewer prescriptions of that product are filled in a calendar month. That is a narrow statement about FDA’s own enforcement priorities, not a patient allowance, and it does not remove the prescriber’s documented significant-difference requirement. Compounded GLP-1s are not routinely available, and not FDA-approved.

FDA’s 503A bulks list explained: Category 1, Category 2, Category 3

FDA issued the first final rule for that list in February 2019. Having evaluated only some of the hundreds of nominated substances, it sorts the rest into interim categories.

• 503A Category 1: nominated with enough information to evaluate. These “may continue to be within the scope of the interim enforcement policy” until FDA decides on inclusion. As of May 14, 2026, Category 1 includes enclomiphene citrate, glutathione, NAD, NADH, pregnenolone and methylcobalamin. Tolerated is not approved.
• 503A Category 2: FDA has identified significant safety risks, so compounding is not permitted. As of May 14, 2026, Category 2 holds six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate (MK-677), kisspeptin-10, and quinacrine hydrochloride for intrauterine use. FDA keeps a separate 503B category 2 table.
• 503A Category 3: nominated without adequate supporting information, and not eligible. GHRP-2, GHRP-6 and mechano growth factor sit here; the first two are also in 503B category 2.

Two rules explain why a peptide can sit in no category at all. A substance nominated on or after January 7, 2025 is no longer placed into these categories, and the peptides people ask about most left the categories because their nominators withdrew the nominations.

Where popular peptides stand in September 2026

This table follows FDA’s bulks-list update of May 14, 2026 and its safety-risk page.

Substance	FDA-approved product?	503A compounding status (September 2026)
Semaglutide	Yes: Ozempic, Wegovy (shortage resolved February 21, 2025)	Component of an approved drug, but Ozempic and Wegovy are available, so compounding requires a prescriber-documented significant difference for that patient; not FDA-approved
Tirzepatide	Yes: Mounjaro, Zepbound (shortage resolved December 19, 2024)	Same as semaglutide: a prescriber-documented significant difference for that patient; not FDA-approved
Bremelanotide (PT-141)	Yes: Vyleesi, for premenopausal women with acquired, generalized HSDD only	Component of an approved drug, and Vyleesi is commercially available, so a compounded PT-141 injection at the same, similar or easily substitutable strength is essentially a copy unless a prescriber determines and documents a significant difference for that patient; a different route, such as a nasal spray, is assessed separately. Compounded forms, nasal sprays and use in men are off-label and not FDA-approved.
Sermorelin	Approved but not marketed: Geref is discontinued	Compounded on the basis that sermorelin acetate is a component of an FDA-approved drug product, Geref (NDA 019863), whose marketing is discontinued; Drugs@FDA records a Federal Register determination that Geref was not discontinued or withdrawn for safety or effectiveness reasons. Sermorelin is not in any of FDA’s three 503A interim categories, and FDA has published no determination on this basis. Compounded sermorelin is not FDA-approved.
Enclomiphene citrate (not a peptide), NAD, NADH, glutathione	No approved product for these	503A Category 1: tolerated pending FDA review; not FDA-approved
BPC-157, TB-500, MOTs-C, KPV, semax, epitalon, emideltide (DSIP)	No; sold online as research chemicals	Not permitted: nominations withdrawn, now on FDA’s “nominated but withdrawn” table; reviewed by the advisory committee in July 2026, no proposed rule since
CJC-1295, AOD-9604, ipamorelin acetate	Нет	Not permitted: nominations withdrawn; ipamorelin acetate also remains 503B category 2 for safety risks
Ibutamoren (MK-677), kisspeptin-10	Нет	503A Category 2: significant safety risks identified; not permitted

BPC-157, TB-500 and the July 2026 advisory meeting: what changed and what did not

1. Previously in Category 2. FDA had placed BPC-157, TB-500 (thymosin beta-4 fragment), CJC-1295, ipamorelin, MOTs-C and AOD-9604 in category 2, citing immunogenicity risk, impurities, and little human safety data.
2. Nominations withdrawn. FDA’s safety-risk page explains that substances “previously in category 2 of the interim policies were withdrawn by the nominators,” and lists them on a separate “nominated but withdrawn” table of 17 substances. Leaving a category table does not make a substance eligible: none of these peptides meets any of the three bases above. Re-nomination can still lead to inclusion on the 503A bulks list through rulemaking, but it no longer earns interim tolerance, because FDA “does not intend to place bulk drug substances nominated on or after January 7, 2025, into these categories.”
3. July 23 to 24, 2026: advisory review. FDA’s Pharmacy Compounding Advisory Committee considered BPC-157, KPV, TB-500 and MOTs-C on July 23, and emideltide (DSIP), semax and epitalon on July 24. Headlines about a favorable committee vote outrun what FDA has published: background materials only, with no minutes, transcript or official results.
4. What has not happened. Committee recommendations are advisory: adding a substance takes a proposed rule, a comment period and a final rule. You can check this yourself: the 503A bulks list at 21 CFR 216.23 holds only a short list of substances, none of these peptides among them, and FDA had published no proposed rule as of September 2026.

A committee vote is not approval, legalization or availability. Revive Longevity does not offer BPC-157, TB-500, CJC-1295, ipamorelin, MOTs-C, AOD-9604, KPV, semax, epitalon or DSIP. See our FDA peptide review.

Research-chemical websites and “not for human consumption”

The disclaimer does the opposite of what buyers assume: FDA reads intended use from labeling, advertising, website copy and the circumstances of sale. In an August 24, 2026 warning letter, FDA addressed a seller offering tirzepatide, tesamorelin and PT-141 “for research use only,” concluded the products were intended for human use, and cited therapeutic claims on the site and the sale of bacteriostatic water.

What this means for a buyer

FDA enforcement of this kind is aimed at sellers: federal law targets introducing unapproved and misbranded drugs into commerce. That does not make a purchase risk-free for the buyer: possessing a prescription drug without a valid prescription may be unlawful under your state’s law, and FDA’s personal importation policy states that it may refuse admission to unapproved drugs ordered from abroad. Practical risks sit on top: nothing verifies identity, potency, purity or sterility, and no prescriber screens for contraindications.

Are peptides controlled substances? DEA scheduling and testosterone

Most peptides are not controlled substances: DEA’s five schedules at 21 CFR part 1308 list controlled drugs by name, and the peptides discussed here are not among them. Scheduling is separate from approval: a peptide can sit outside DEA’s schedules and still be an unapproved drug no pharmacy may compound.

Testosterone, a steroid hormone not a peptide, is the common exception. It is listed by name as an anabolic steroid in Schedule III at 21 CFR 1308.13(f), so the prescriber needs a DEA registration and Controlled Substances Act rules apply. In June 2026, after reviewing new data including the TRAVERSE trial, FDA asked manufacturers to update testosterone labeling, including removing the limitation of use about age-related hypogonadism. FDA’s testosterone page still states that none of the FDA-approved testosterone products is approved for men with low testosterone levels who lack an associated medical condition. See our guide on testosterone as a controlled substance.

State licensing, LegitScript certification, and how to verify a provider

Federal law decides what may be compounded; state law decides who may prescribe and dispense it. The Federation of State Medical Boards reports, in its board-by-board overview of telemedicine policies, that every state medical board requires physicians practicing telemedicine to be licensed where the patient is located, or registered there if the state keeps an interstate-practice registry. Physician associates and nurse practitioners answer to their own boards, and the pharmacy must be licensed to ship to your state.

LegitScript Healthcare Certification, which Revive Longevity holds, is a private third-party certification, not a government license: one independent signal about how a provider operates, not FDA approval or evidence that a treatment works.

A three-point verification checklist

1. Confirm the prescriber’s license on your state medical or nursing board site, and the pharmacy’s on your state pharmacy board.
2. Ask, product by product, whether it is FDA-approved or compounded, and which of the three 503A bases covers a compounded ingredient.
3. Treat two claims as warning signs: “research use only” products, and any peptide on FDA’s category 2 or withdrawn tables described as now legal.

Our guide to choosing a licensed online peptide clinic goes deeper: verify credentials directly, ours included.

How Revive approaches peptide therapy

Revive Longevity is a LegitScript-certified telehealth clinic with licensed U.S. providers in all 50 states, and prescribes only inside the lawful lanes above: FDA-approved products, or preparations compounded by a state-licensed 503A pharmacy for an individual patient after a provider’s evaluation. Our medical content is reviewed by Diana Medina, PA-C, a board-certified Physician Associate. There are no “research use only” products and no treatment without a consultation. Compounded therapies, including sermorelin, enclomiphene, NAD+, glutathione, PT-141 and tirzepatide, are not FDA-approved, and FDA has not evaluated them for safety, effectiveness or quality.

Pricing on the странице с ценами: Sermorelin $179, Enclomiphene $159, PT-141 $199, Tirzepatide $279, all per 4 weeks, subject to change and to eligibility. Because FDA-approved products exist for tirzepatide (Mounjaro, Zepbound) and bremelanotide (Vyleesi), a 503A pharmacy may not regularly compound what is essentially a copy of them, and the prescriber applies that rule to the specific form and strength case by case. Compounded tirzepatide and PT-141 are not FDA-approved, and PT-141 use in men is off-label. A licensed provider, not a price list, decides what is appropriate.

Часто задаваемые вопросы

Are peptides legal to buy online in the U.S.?

Yes, through a licensed provider and a state-licensed pharmacy, when the peptide is an FDA-approved drug or a lawfully compounded prescription. The prescription is what makes it lawful for you to possess and use, and without one, possessing a prescription drug may be unlawful under your state’s law. “Research use only” peptides are different: FDA treats them as unapproved drugs.

Is BPC-157 legal now that the FDA advisory committee has reviewed it?

Not yet. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 at its July 23 to 24, 2026 meeting, but committee recommendations are advisory: FDA decides, and adding a substance takes a proposed rule and a final rule. FDA has published no official results from that meeting and no proposed rule as of September 2026, and BPC-157 is not on the 503A bulks list codified at 21 CFR 216.23, so it cannot be lawfully compounded.

Are peptides controlled substances?

Most are not. The peptides discussed here are not listed in DEA’s schedules at 21 CFR part 1308. Testosterone, a steroid hormone rather than a peptide, is in Schedule III at 21 CFR 1308.13(f), so the prescriber needs a DEA registration.

Is compounded semaglutide or tirzepatide still legal?

Only where the prescriber determines and documents that the compounded product contains a change producing a significant difference for that individual patient. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, so a 503A pharmacy may not regularly compound what is essentially a copy of an available approved drug. Compounded GLP-1s are not routinely available, and never FDA-approved.

Is sermorelin legal?

Sermorelin acetate is a component of an FDA-approved drug product, Geref (NDA 019863), whose marketing is discontinued; Drugs@FDA records a Federal Register determination that Geref was not discontinued or withdrawn for safety or effectiveness reasons. Pharmacies compound sermorelin on that basis. Sermorelin is not in any of FDA’s three 503A interim categories, and FDA has published no determination on this basis. Compounded sermorelin is not FDA-approved, and a provider and pharmacy decide whether it fits you.

How can I tell if a peptide clinic is legitimate?

Check the prescriber’s license on your state medical board site and the pharmacy’s on your state board of pharmacy site, confirm both are valid where you live, and ask whether each product is FDA-approved or compounded. LegitScript certification is a private check on how a provider operates, not FDA approval.